Baclofen intrathecal injection

Drug Profile

Baclofen intrathecal injection

Alternative Names: Gablofen

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator CNS Therapeutics
  • Developer CNS Therapeutics; Mallinckrodt LLC
  • Class Aminobutyric acids; Antispastics; Muscle relaxants; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Muscle spasticity

Most Recent Events

  • 13 Feb 2017 Chemical structure information added
  • 30 Jan 2017 Piramal Enterprises enters into an agreement to acquire spasticity and pain management therapeutics including baclofen intrathecal injection from Mallinckrodt (9210845; 9210919)
  • 29 Sep 2016 Registered for Muscle spasticity in Sweden, Netherlands, Belgium, Germany, Italy, Spain, United Kingdom, Denmark (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top